Introduction: Resistance to EGFR tyrosine kinase inhibitors develops in patients with EGFR-mutant lung cancers. New treatments are needed to address resistance not mediated by EGFR T790M; preclinical evidence suggests that the Janus kinase/signal transducers and activators of transcription signaling pathway is important in acquired resistance to EGFR-directed therapy.
Introduction
EGFR tyrosine kinase inhibitors (TKIs) are effective for the treatment of EGFR-mutant lung cancers. However, tumors in all patients develop resistance to these agents. [1] [2] [3] [4] In 60%, resistance to EGFR TKIs is caused by an acquired EGFR T790M mutation. 5, 6 Osimertinib, a third-generation EGFR inhibitor that targets EGFR T790M, induces durable regressions in those tumors that harbor EGFR T790M. 7 In addition to acquired EGFR mutations, resistance mechanisms can be separated into general categories: upregulation of parallel signaling pathways such as MNNG HOS Transforming gene (MET) or gene erb-b2 receptor tyrosine kinase 2 (HER2) amplification, 8, 9 acquired mutations in other oncogenes such as BRAF or phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA), 6, 10 or histologic transformation including small cell or epithelial to mesenchymal transformation. 11 Many investigational agents have been studied to address the non-EGFR T790M-mediated mechanisms of resistance. Nearly all studies have reported little or no efficacy of treatments in the setting of acquired resistance to EGFR TKIs without T790M. 12 Interleukin-6 (IL-6)/Janus kinase (JAK)/signal transducers and activators of transcription (STAT) signaling contributes to oncogenesis. STAT proteins are transcription factors that are involved in critical physiologic functions, including cell proliferation, apoptosis, and differentiation. Persistent STAT3 activation is oncogenic, regulating growth factor signaling, angiogenesis, survival, and metastases. 13, 14 JAK tyrosine kinases activate STATs and can be mutated, leading to constitutive activation, but they can also be activated by upstream signaling or feedback loops. Systemic inflammation is also a driver of cancer initiation and progression during which inflammation is driven primarily by IL-6, a cytokine that also uses JAK/STAT signaling. In patients with pancreatic cancer and evidence of systemic inflammation, early studies combining a JAK1/2 inhibitor (ruxolitinib) with chemotherapy resulted in improved overall survival compared with that with chemotherapy alone. 15 JAK/STAT signaling has been implicated by several groups as a modulator of response and resistance to EGFR TKIs. Phosphorylated signal transducer and activator of transcription 3 (pSTAT3) is present in nearly all EGFRmutant lung cancers cells, with two-thirds of EGFR-mutant tumors with acquired resistance to erlotinib having high expression of pSTAT3. 16, 17 EGFR activation results in downstream STAT3 activation in a JAK-dependent manner, presumably through fibroblast growth factor receptor and IL-6 signaling. 16, 18 Treatment of EGFR-mutant cell lines with erlotinib dramatically increased pSTAT3, whereas knockdown of STAT3 by RNA interference led to increased apoptosis and enhanced sensitivity to erlotinib. Conversely, constitutively activating STAT3 induced erlotinib resistance. 18 Similarly, Yao et al. found that inducing inflammation resulted in increased IL6/JAK/STAT signaling that decreased sensitivity to erlotinib in an EGFRmutant preclinical model. 19 Cotreatment with erlotinib and ruxolitinib (a JAK 1/2 inhibitor) inhibited STAT3 activation. 18 In EGFR-mutant (HCC4006) xenografts, the combination of erlotinib and ruxolitinib slowed tumor growth more effectively than did erlotinib alone. 18 In addition, a phase 1 study of OPB51602, an inhibitor of STAT3 phosphorylation, demonstrated responses in patients with EGFR-mutant lung cancers, who comprised 80% of the patients with lung cancer who responded to therapy. 20 In addition to modulating initial responses, IL-6/JAK/ STAT3 signaling may mediate de novo and acquired resistance to afatinib and erlotinib. 21 Inhibition of STAT3 heightened response to afatinib in EGFR T790M-containing cell lines. STAT3 activation in the setting of EGFR TKI treatment appears to be JAK dependent, and EGFR TKI therapy with concurrent inhibition of JAK/ STAT signaling abrogated proliferation in EGFR T790M-containing cell lines and xenograft models. 21 An independent group developed resistant cells by exposing EGFR-mutant cells (PC-9) to continuous erlotinib and demonstrated that cotreatment with erlotinib and a JAK inhibitor (JSI-124) restored sensitivity to erlotinib in these resistant cells. 22 The combination was similarly effective in an EGFR TKI-resistant xenograft model. Additional preclinical studies with AZD 1480 (another JAK1/2 inhibitor) illustrated that EGFR-mutant cell lines and xenografts (with and without resistance to gefitinib) were sensitive to inhibition with AZD1480. 23 Importantly, JAK2 inhibition restored sensitivity to erlotinib in EGFR TKI-resistant cell lines and xenograft models. Mechanistically, JAK2 inhibition uncoupled EGFR from its negative regulators, increasing EGFR abundance and heterodimerization of mutant and wild-type EGFR subunits, the activity of which was then able to be blocked by EGFR TKIs. 17 Exosomes, which are cell-derived vesicles that contain proteins, RNA, and DNA from their cell of origin, are present in the peripheral blood and can be collected and analyzed. 24 Tumor-derived exosomes can be a means of cell-cell signaling, altering their environment to enhance growth and metastasis. 25 Exosomal protein signatures have prognostic significance in patients with melanoma and can predict stage and survival outcome. 25 EGFR-mutant lung cancers that express the mutant EGFR and other signaling molecules secrete exosomes into the peripheral blood. 26, 27 We hypothesized that exosomal protein expression can recapitulate the signaling that occurs in tumors in response to targeted therapies and may serve as a surrogate for tumor tissue.
These preclinical and clinical studies represent converging lines of evidence that support the study of combination EGFR and JAK inhibition in EGFR-mutant lung cancers that are resistant to EGFR TKIs. On the basis of these data, we assessed the effectiveness and toxicity of the combination of erlotinib and ruxolitinib in patients with EGFR-mutant lung cancers with acquired resistance to EGFR TKIs and utilized tumor exosomes collected from peripheral blood to assess changes in protein expression with treatment.
Patients and Methods
The trial was a prospective, single-center phase 1/2 study in patients with EGFR-mutant lung cancers with acquired resistance to EGFR TKIs. The primary end point of the phase 1 portion of the study was the identification of the maximum tolerated dose (MTD) of the combination of daily oral erlotinib and twice daily oral ruxolitinib. The primary end point of the phase 2 portion was assessment of efficacy using the overall response rate to the combination. Secondary objectives included assessments of toxicity, progression-free survival (PFS), and overall survival. The trial was conducted after approval of the institutional review board at Memorial Sloan Kettering Cancer Center. The study was registered at ClinicalTrials.gov (NCT02155465).
Patients
Patients had stage IV or recurrent lung cancers with a somatic activating mutation in EGFR. They must have demonstrated radiographic progression during prior treatment with erlotinib and undergone a repeat biopsy at the time of acquired resistance to erlotinib. Prior intervening chemotherapy was allowed. All patients were required to have been receiving erlotinib monotherapy for at least 2 weeks immediately before the study's start. Additionally, patients had to have adequate organ function and a Karnofsky performance status of 70% or higher.
Study Design
The phase 1 portion utilized a standard 3 plus 3 dose escalation. Three dose levels were utilized; they included erlotinib, 150 mg orally daily, and escalating doses of ruxolitinib (10 mg, 15 mg, and 20 mg orally twice daily, respectively). The starting dose level of ruxolitinib was 10 mg orally twice daily, which was the lowest dose studied in the phase 1/2 study of ruxolitinib. 28 Three patients were enrolled at each dose level and assessed for one cycle without dose-limiting toxicity (DLT) before dose escalation. Each cycle lasted 3 weeks, and patients who did not experience a DLT continued treatment at the assigned dose until progression of disease, unacceptable toxicity, or withdrawal of informed consent, with no intrapatient dose escalation.
Six patients needed to be treated at a dose level before it was declared the MTD. Once the MTD was determined, patients were enrolled in the phase 2 portion of the study to determine efficacy of the combination of erlotinib and ruxolitinib. Patients received erlotinib and ruxolitinib at the MTD established in the phase 1 portion. For the phase 2 portion, patients were allowed to continue their previous stable dose of erlotinib if less than 150 mg orally daily.
A Simon minimax two-stage trial design was utilized to assess the primary end point of response rate at 6 weeks (two cycles). Sixteen patients were treated in the first stage of the study, with patients treated at the MTD in the phase 1 portion included toward accrual of the phase 2 portion. If two or more responses were seen, the study would move on to the second stage in which an additional nine patients would be treated.
Study Assessments
Patients were assessed weekly during cycle 1 and then every 21 days. Patient history, physical examination, complete blood count, and serum chemistry studies (including measurement of C-reactive protein [CRP] level) were performed at each visit. Toxicity was graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 4. DLT was defined as any grade 3 or greater nonhematologic toxicities, with diarrhea, nausea, and vomiting needing to be grade 3 for 72 hours despite maximal supportive care to qualify as a DLT. Any grade 4 hematologic toxicity lasting longer than 5 days was considered a DLT. Response to therapy was assessed by interval imaging every 6 weeks with a CT scan with response evaluated per RECIST 1.1.
Statistical Analysis
Safety and tolerability were summarized using descriptive statistics. The safety population comprised all patients who received at least one dose of the study treatment. Response rates were calculated using binomial proportions and exact 95% confidence intervals (CIs). PFS was estimated using the Kaplan-Meier method and defined as the time from start of study therapy until progression or death. Patients who did not experience the event of interest were censored at the date on which they left the study or date of last assessment if they were still receiving study therapy.
Exosomal Analysis
H1975 cell lines (purchased from the American Type Culture Collection [Manassas, VA]) were cultured in exosome-depleted fetal bovine serum-containing media 25 and treated with ruxolitinib, 1 mM (Chemietek, Indianapolis, IN), and erlotinib, 125 nM (Chemietek), and EGFR levels were determined by Western blot analysis from cell extracts and isolated exosomes. For immunoblotting assays, cells or exosomes were lysed in buffer (50 mmol/L of Tris at pH 7.5, 150 mmol/L of NaCl, 5 mg/ mL of aprotinin, pepstatin, 1% NP-40, 1 mmol/L of etylenediaminetetraacetic acid, 0.25% deoxycholate, and protease inhibitor cocktail tablet [Sigma, St. Louis, MO]). Proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis, transferred to polyvinylidene fluoride membranes, and blotted with antibodies against the EGFR, phosphorylated EGFR (pEGFR), tsg101, tubulin, and glyceraldehyde-3-phosphate dehydrogenase (Cell Signaling Technology, Danvers, MA).
Plasma (10 mL) was collected from patients before the commencement of therapy and at each visit and processed within 4 hours of collection. The conditioned media from 10 7 cancer cells and/or patient plasma was centrifuged for 20 minutes at 3000 g at 4 C. The supernatant was subsequently centrifuged for 30 minutes at 12,500 g at 4 C. The supernatant was transferred and centrifuged at 100,000 g for 90 minutes at 4 C. The exosomes were resuspended in 25 mL of phosphatebuffered saline (PBS) and loaded onto a 5-mL 30% sucrose cushion to deplete microvesicles from extracellular proteins (300 g/L of sucrose and 24 g/L of Tris base, pH 7.4). Samples were centrifuged at 100,000 g for 90 minutes 4 C. Next, 3.5 mL of the cushion, containing exosomes, was diluted with 10 mL of PBS and centrifuged at 100,000 g for 90 minutes at 4 C. The supernatant was discarded and the pellet resuspended in 25 mL of PBS. The number and size of exosomes were determined by particle analysis with a NanoSight instrument (Malvern Instrument, Malvern, United Kingdom). Protein concentration was determined by Bradford assay. Exosomal EGFR levels were measured by enzyme-linked immunosorbent assay, as described by the manufacturer (AbCam, Cambridge, United Kingdom) using 2 mg of protein, with the measurement performed in triplicate.
Results

Patients
From June 2014 to September 2015, 22 patients were enrolled. Twelve patients were treated in the phase 1 portion of the study, and 10 patients were treated at the MTD in the phase 2 portion. In total, 16 patients were treated at the MTD. The clinical characteristics of all patients are listed in Table 1 . Twenty-one patients discontinued the study because of progressive disease, and one was withdrawn for toxicity.
MTD and Toxicity
There were no DLTs seen at any dose levels. The third dose level, erlotinib, 150 mg daily, and ruxolitinib, 20 mg twice daily, was declared the MTD. All 22 patients were evaluable for toxicity. The most frequent (10%) drug-related adverse events were anemia, diarrhea, elevation in liver function test results, fatigue, decreased white blood cell count, dry skin, rash, and anorexia ( Table 2) . No deaths were seen during the study and most drug-related toxicities were grade 1 and 2. Two patients required dose reductions. One patient was withdrawn from the study for possible pneumonitis. Progressive dyspnea and hypoxic respiratory failure developed in the patient in the setting of bilateral ground glass opacities seen on imaging. She responded to steroids, and neither drug was restarted.
Efficacy
All 22 patients had baseline radiographic assessments. Three patients left the study before the first follow-up radiographic assessment (all because of clinical progression) and were counted as nonresponders in our intent-to-treat analysis. One patient of 22 had a confirmed partial response for an overall response rate of 5% (95% CI: 0-13). Nine patients had a decrease in the sum of their target lesions (Fig. 1) . The median PFS was 2.2 months (95% CI: 1.5-4.1); the range was 1 to 17 
Correlative Exosomal Analysis
We previously demonstrated that inhibition of JAK in cell lines and xenograft models of erlotinib-resistant lung cancers led to an increase in EGFR expression and signaling that was potently suppressed when combined with erlotinib. 17 We hypothesized that EGFR expression on exosomes might recapitulate what was observed in cell lines. We examined EGFR levels from H1975 (erlotinib resistant) cells and exosomes after treatment with combination JAK1/2 inhibitor and erlotinib. We observed a decrease in EGFR expression in both cell lines and exosomes, suggesting that the changes observed in cells are recapitulated in tumor-derived exosomes ( Fig. 2A) . We next asked whether EGFR levels could be measured from our patient-derived exosomes and determine whether their levels changed upon treatment with ruxolitinib and erlotinib. Plasma was collected from all patients before the initiation of therapy and 14, 30, or 60 days after commencement of therapy. Seventeen of 22 patients had evaluable exosomes (sufficient number and matched pretreatment and posttreatment samples processed within 4 hours of collection). The concentration of exosomal protein per milliliter of plasma was approximately 4 mg/mL and did not significantly change with therapy (data not shown). We measured exosomal EGFR levels by enzyme-linked immunosorbent assay, which is quantitative and does not require the amounts required for Western blot analysis. Notably, the EGFR antibody used does not distinguish between mutant and wild-type EGFR. In this cohort of patients, the range of EGFR varied between 10 and 120 pg/2 mg of exosomal protein whereas EGFR levels in exosomes from individuals without evidence of cancer were between 4 and 8 pg/2 mg of exosomal protein (Fig. 2B) . We determined that in four of 17 matched samples, exosomal EGFR levels were reduced after the initiation of therapy; in four of 17, no changes were observed, and in nine of 15, EGFR levels increased (see Fig. 2B ). Notably, the three patients who remained in the study the longest (6-, 12-, and 17-month PFS) had a reduction in exosomal EGFR with therapy. Those patients whose exosomal EGFR levels did not change or increased had been receiving therapy for less than 4 months, suggesting a possible relationship between longer PFS and reduction in exosomal EGFR. These exploratory observations suggest that exosomal EGFR levels reflect the effects of combined ruxolitinib and erlotinib on tumor expression of EGFR and are predicted to decline on the basis of our preclinical data. 17 
Discussion
This was the first study assessing the combination of a JAK and an EGFR inhibitor for the treatment of patients with EGFR-mutant lung cancers with acquired resistance to EGFR TKIs. The combination of erlotinib and ruxolitinib was well tolerated. The most significant toxicity was anemia; most patients were asymptomatic, and a dose reduction because of anemia was not required. Two patients required dose reductions during the study; both were for asymptomatic neutropenia. The incidences of anemia, neutropenia, and leukopenia were similar to what was seen in the study of ruxolitinib with or without capecitabine in pancreatic cancer. 29 Only one partial response lasting 12 months was seen with the combination or erlotinib and ruxolitinib in patients with EGFR-mutant lung cancers and acquired resistance to EGFR TKI therapy. The patient had been receiving EGFR TKI therapy for a prolonged period immediately before study enrollment. The tumor in the one subject with a partial response harbored an EGFR T790M mutation, as did those of the other two subjects with the most tumor shrinkage during the study. Unfortunately, the partial responder did not have any tumor tissue available to perform additional molecular analyses. We did not see an association with CRP and response to erlotinib and ruxolitinib. There are no plans for future development of the combination of erlotinib and ruxolitinib.
Although options for patients with EGFR-mutant lung cancer and EGFR T790M-mediated acquired resistance have improved with the recent approval of osimertinib (an EGFR T790M inhibitor), options remain limited for patients with non-EGFR T790M-mediated resistance. Previous combination strategies using erlotinib have not proved fruitful. 12 The only combination strategy that has shown efficacy in patients with non-EGFR T790M-mediated resistance has been afatinib and cetuximab, use of which is limited by significant toxicity. 30 Future therapeutic studies should focus on the potential of immunotherapy as well as on molecular agents that address histologic transformation as novel treatment with potential in this population. For patients with EGFR T790M-mediated resistance, combinations strategies utilizing the EGFR T790M inhibitors such as osimertinib will be important to attempt to prevent or reverse resistance to these new agents. Among these, a phase 1/2 study of osimertinib and a JAK inhibitor is planned for patients with EGFR-mutant lung cancers with EGFR T790M and acquired resistance to EGFR TKIs.
Our preclinical data demonstrated that changes in EGFR expression in cancer cells could also be observed in exosomes in response to therapy, suggesting their potential role as a pharmcodynamic biomarker. Similar Figure 2 . Exosome EGFR levels in response to erlotinib and ruxolitinib. (A) H1975 (EGFR L858R-T790M) cancer cells were treated with vehicle (C) or ruxolitinib (1 mM) and erlotinib (125 nM) for 48 hours, and both cell lysates and lysates from exosomes isolated from the conditioned media of these cells were analyzed for EGFR, tubulin, and tsg101 (an exosomal protein) by Western blot analysis. (B) Exosomes were isolated from the plasma of patients before therapy (C1D1) and 2 weeks, 30 days, or 60 days after the commencement of ruxolitinib therapy. Exosomes from four healthy individuals (healthy controls) were isolated from plasma. Protein levels were measured and EGFR concentration (pg/mL) was determined for 2 mg of exosomal protein. Reductions in exosomal EGFR levels after the initiation of therapy are denoted in orange, no change is denoted in gray, and increases are denoted in blue. Time (months) receiving treatment (Rx) is indicated below each patient. Data are reported as the mean ± SD of three independent experiments. p Values refer to Student's t test. C, control; TKI, EGFR tyrosine kinase inhibitor; Ji, Janus Kinus inhibitor; *p < 0.05; **p < 0.005.
preclinical observations have been made in other cell types; specifically, treatment of brain, epidermal, breast, prostate, colon, and pancreatic cancer cells with secondgeneration kinase inhibitors promoted the release of extracellular vesicles containing EGFR and pEGFR. 31 In contrast to preclinical models, here we examined EGFR expression in patient-derived exosomes, which was determined to be approximately 10-fold higher than in healthy controls, suggesting that EGFR could be tumor enriched as these patients had considerable disease burden. Notably, we also examined pEGFR levels in circulating exosomes, which were undetectable. Interestingly, EGFR levels varied in response to therapy after 2 weeks, which we hypothesized is insufficient to reflect a therapeutic response/progression and is thus more likely a measure of EGFR changes within the tumor in response to combination ruxolitinib/erlotinib. The three patients who remained in the study the longest (6, 12, and 17 months), including the partial responder, had a reduction in exosomal EGFR levels at 2 weeks into the study. Despite a lack of efficacy of ruxolitinib and erlotinib in this patient population, our exploratory data suggest further investigation of the use of patients' expression of exosomal protein as a potential surrogate for therapeutic tumor-specific on-target effects.
